^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
RITUXAN (rituximab) is a CD20-directed cytolytic antibody indicated for the treatment of...Adult patients with Non-Hodgkin’s Lymphoma (NHL)...Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent....Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.
Secondary therapy:
CHOP; Chemotherapy
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation

Excerpt:
...CD 20 positive...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

Excerpt:
...Patients with histological verified CD20-positive B-Cell-Lymphomas of the following entities...
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

2101 Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Published date:
11/04/2020
Excerpt:
Multi-institutional Phase II study (NCT01859819). Patients (3-31 years) with CD20+ B-NHL with good risk (FAB Group...Our results demonstrate the feasibility of careful reduction of anthracycline dose intensity with the addition of dose-dense rituximab...Our results demonstrate a 100% EFS/OS with a reduction to only 50mg/m2 total dose of anthracycline.
Secondary therapy:
doxorubicin hydrochloride + methotrexate + liposomal cytarabine
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

[Clinical Efficiency of Rituximab Combined with Autologous Hematopoietic Blood Stem Cell Transplantation for Treatment of CD20 + B non.Hodgkin Lymphoma]

Excerpt:
...83 patients with refractory/recurrent CD20+ B.NHL who were treated with auto.HSCT in our department were enrolled. The patients were divided into 2 groups: 57 patients in Rituximab group, and 26 patients in control group(without Rituximab)…. Subgroup analysis showed that: compared with the treatment group in which using R in the whole courses(before and after transplantation, and collection of stem cells) was superior to the control group in both OS and EFS, with the OS 97% vs 87.5% (P>0.05) and EFS 97% vs 76.2% (P=0.05) respectively.
DOI:
10.19746/j.cnki.issn.1009-2137.2021.01.013